Improved clonality detection in B‐cell lymphoma using a semi‐nested modification of the BIOMED‐2 PCR assay for IGH rearrangement: A paraffin‐embedded tissue study. Issue 9 (September 2017)

• Record Type: Journal Article
• Authors: Sakamoto, Yuma; Masaki, Ayako; Aoyama, Satsuki; Han, Shusen; Saida, Kosuke; Fujii, Kana; Takino, Hisashi; Murase, Takayuki; Iida, Shinsuke; Inagaki, Hiroshi
• Is Part Of: Pathology international. Volume 67:Issue 9(2017)
• Page Start: 453
• Page End: 460
• Publication Date: 2017-09
• Subjects: B‐cell lymphomas -- BIOMED‐2 PCR assay -- formalin‐fixed paraffin‐embedded tissues -- re‐amplification -- semi‐nested modification; Pathology -- Periodicals; 616.07
• DOI: 10.1111/pin.12566
• Languages: English
• ISSNs: 1320-5463

Abstract

Abstract : The BIOMED‐2 PCR protocol for targeting the IGH gene is widely employed for detecting clonality in B‐cell malignancies. Unfortunately, the detection of clonality with this method is not very sensitive when paraffin sections are used as a DNA source. To increase the sensitivity, we devised a semi‐nested modification of a JH consensus primer. The clonality detection rates of three assays were compared: the standard BIOMED‐2, BIOMED‐2 assay followed by BIOMED‐2 re‐amplification, and BIOMED‐2 assay followed by semi‐nested BIOMED‐2. We tested more than 100 cases using paraffin‐embedded tissues of various B‐cell lymphomas, and found that the clonality detection rates with the above three assays were 63.9%, 79.6%, and 88.0%, respectively. While BIOMED‐2 re‐amplification was significantly more sensitive than the standard BIOMED‐2, the semi‐nested BIOMED‐2 was significantly more sensitive than both the standard BIOMED‐2 and BIOMED‐2 re‐amplification. An increase in sensitivity was observed in all lymphoma subtypes examined. In conclusion, tumor clonality may be detected in nearly 90% of B‐cell lymphoma cases with semi‐nested BIOMED‐2. This ancillary assay may be useful when the standard BIOMED‐2 fails to detect clonality in histopathologically suspected B‐cell lymphomas.